A phase II study of first-line erlotinib in patients (pts) with stage IIIB/IV non-small-cell lung cancer (NSCLC) including dose escalation to toxicity in current and former smokers (C/FS)

被引：2

作者：

Besse, B.

Smit, E. F.

Felip, E.

Siena, S.

Blackhall, F.

Barlesi, F.

Giaccone, G.

机构：

[1] Inst Gustave Roussy, Villejuif, France

[2] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands

[3] Vall dHebron Univ Hosp, Barcelona, Spain

[4] Osped Niguarda Ca Granda, Milan, Italy

[5] Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England

[6] Assistance Publ Hop Marseille, Marseille, France

[7] NCI, Bethesda, MD 20892 USA

来源：

关键词：

D O I：

10.1200/jco.2008.26.15_suppl.8111

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8111

引用

页数：1